Potential value of serum brain-derived neurotrophic factor, vascular endothelial growth factor, and S100B for identifying major depressive disorder in knee osteoarthritis patients

Zhang, Peng; Xiong, Yi; Wang, Bangjun; Zhou, Yi; Wang, Zijian; Shi, Jiaqi; Li, Chao; Lu, Xinyan; Chen, Gang

doi:10.3389/fpsyt.2022.1019367

Cited by 3 publications

(1 citation statement)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 55 VEGF is thought to have antidepressant-like effects, and VEGF signalling mediates cell proliferation of antidepressants through Flk-1 and causes behavioural changes in chronic antidepressant models. 56 Warner-Schmidt reported that in a rat model of depression, VEGF expression in the hippocampus was elevated and was regulated by selective serotonin reuptake inhibitors or selective serotonin/norepinephrine reuptake inhibitors, which were used for antidepressant treatment. 57 EGF promotes the growth and development of the nervous system.…”

Section: Discussionmentioning

confidence: 99%

Network pharmacology analysis of a patented Chinese herbal medicine for alleviating anxiety disorder in in vitro fertilization-embryo transfer

Liu,

Hu,

Feng

et al. 2024

Journal of Traditional and Complementary Medicine

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Network pharmacology analysis of a patented Chinese herbal medicine for alleviating anxiety disorder in in vitro fertilization-embryo transfer

Liu,

Hu,

Feng

et al. 2024

Journal of Traditional and Complementary Medicine

View full text Add to dashboard Cite

Exploring Risk Factors for Comorbid Depression in Osteoarthritis: A Scoping Review Protocol

Bogensberger,

Schaffler-Schaden,

Perl

et al. 2024

Preprint

View full text Add to dashboard Cite

IntroductionGlobally, osteoarthritis (OA) is the most prevalent musculoskeletal disease, affecting approximately 600 million people. It is characterised by progressive degeneration of the articular cartilage, osteophyte formation, and asymmetric joint space narrowing, leading to pain, stiffness, and functional impairment. The current focus of disease management is on symptom relief and functional improvement. However, these interventions frequently do not provide adequate outcomes. This may be attributed to a lack of consideration for contextual factors, including the presence of comorbidities such as depression. Several studies indicate that depression is highly prevalent, affecting up to 20% of OA patients. As depression is known to be a multifactorial disorder, there are various risk factors that may increase the likelihood of comorbid depression in patients with OA. Consequently, the scoping review’s objective is to map the existing literature on risk factors for comorbid depression in individuals with OA. Furthermore, the review is expected to provide important information for further in-depth investigation and the development of predictive tools to support the early identification of patients with OA at risk of comorbid depression.Methods and AnalysisThe intended review will target studies reporting risk factors for comorbid depression in individuals with OA. All available primary and grey literature will be considered for inclusion. Only articles published in English or German will be included in the review. The review will follow the format specified by the Preferred Reporting Items for Systematic Reviews and Meta-Analyses Extension for Scoping Reviews (PRISMA-ScR) and the JBI Manual for Evidence Synthesis. Original research in published and unpublished literature from inception until August 2024 will be included into the review. The databases to be searched will include PubMed, EMBASE, PsychInfo, and Web of Science. In addition, further literature will be identified by searching the reference lists of the included studies. Three reviewers will independently screen the identified studies for final inclusion. The data will be extracted and presented in tabular form and in a narrative summary that aligns with the review’s objective. Furthermore, a quality assessment of the included studies will be conducted using appropriate tools, and the results will be incorporated into the synthesis. Any disagreements that arise between the reviewers will be resolved through discussion or with an additional reviewer.Ethics and DisseminationEthics committee approval will not be required because only published and publicly available data will be examined to answer the research question of the scoping review. We will not collect any personal information or any information that requires ethical approval.Strengths and LimitationsThis protocol adheres to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for Scoping Reviews checklist format, thereby ensuring best practice in conducting this review.The broad eligibility criteria and the conduct of the search in multiple databases with publication dates starting at inception will provide a comprehensive overview on the research area.The review will be conducted by a multidisciplinary team.A quality assessment of the included studies will facilitate a more accurate interpretation of the review’s findings and their significance for policy and practice.The review is limited to articles published in English and German.

show abstract

Inflammation and Late-Life Depression: Unraveling the Complex Relationship and Potential Therapeutic Strategies

Xia,

Chen,

Shao

et al. 2023

Front. Biosci. (Landmark Ed)

View full text Add to dashboard Cite

The origins of late-life depression are multifaceted and remain challenging to fully understand. While the traditional monoamine neurotransmitter hypothesis provides some insights, it falls short in explaining the disease’s onset and progression, leaving treatments often less than optimal. There is an emergent need to uncover new underlying mechanisms. Among these, the “inflammation hypothesis” has been gaining traction in scientific discussions regarding late-life depression. There is compelling evidence linking inflammation processes to the emergence of this form of depression. This review delves into the nuanced relationship between inflammation and late-life depression, emphasizing the pivotal role and implications of inflammation in its pathogenesis. Changes in Ca2+ homeostasis, cytokine levels, brain-derived neurotrophic factor (BDNF), white cell ratios, and the involvement of the NOD-, LRR-, and Pyrin domain-containing protein 3 (NLRP3) inflammasome have all been suggested as potential biomarkers that tie inflammation to late-life depression. Furthermore, factors such as aging-induced DNA damage, oxidative stress, mitochondrial impairments, disruptions in the hypothalamic-pituitary-adrenal axis, activated microglia and associated neuroinflammation, as well as the gut-brain axis dynamics, could serve as bridges between inflammation and depression. Deepening our understanding of these connections could usher in innovative anti-inflammatory treatments and strategies for late- life depression.

show abstract

Potential value of serum brain-derived neurotrophic factor, vascular endothelial growth factor, and S100B for identifying major depressive disorder in knee osteoarthritis patients

Cited by 3 publications

References 48 publications

Network pharmacology analysis of a patented Chinese herbal medicine for alleviating anxiety disorder in in vitro fertilization-embryo transfer

Network pharmacology analysis of a patented Chinese herbal medicine for alleviating anxiety disorder in in vitro fertilization-embryo transfer

Exploring Risk Factors for Comorbid Depression in Osteoarthritis: A Scoping Review Protocol

Inflammation and Late-Life Depression: Unraveling the Complex Relationship and Potential Therapeutic Strategies

Contact Info

Product

Resources

About